Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.3 (
phospholipase C
)
18,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have recently found the calcium dependent glycogenolytic effect of a pancreastatin on rat hepatocytes and the mobilization of intracellular calcium. To further investigate the mechanism of action of pancreastatin on liver we have studied its effect on guanylate cyclase, adenylate cyclase, and
phospholipase C
, and we have explored the possible involvement of GTP binding proteins by measuring GTPase activity as well as the effect of pertussis toxin treatment of plasma liver membranes on the pancreastatin stimulated GTPase activity and the production of cyclic GMP and myo-inositol 1,4,5-triphosphate.
Pancreastatin
stimulated GTPase activity of rat liver membranes about 25% over basal. The concentration dependency curve showed that maximal stimulation was achieved at 10(-7)M pancreastatin (EC50 = 3 nM). This stimulation was partially inhibited by treatment of the membranes with pertussis toxin. The effect of pancreastatin on guanylate cyclase and
phospholipase C
were examined by measuring the production of cyclic GMP and myo-inositol 1,4,5-triphosphate respectively.
Pancreastatin
increased the basal activity of guanylate cyclase to a maximum of 2.5-fold the unstimulated activity at 30 degrees C, in a time- and dose-dependent manner, reaching the maximal stimulation above control with 10(-7) M pancreastatin at 10 min (EC50 = 0.6 nM). This effect was completely abolished when rat liver membranes had been ADP-ribosylated with pertussis toxin. On the other hand, adenylate cyclase activity was not affected by pancreastatin. Phospholipase C activity of rat liver membranes was rapidly stimulated (within 2-5 min) at 30 degrees C by 10(-7) M pancreastatin, reaching a maximum at 15 min.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Pancreastatin activates pertussis toxin-sensitive guanylate cyclase and pertussis toxin-insensitive phospholipase C in rat liver membranes. 791 48
Pancreastatin
is a 49 amino acid peptide first isolated, purified and characterized from porcine pancreas. Its biological activity in different tissues can be assigned to the C-terminal part of the molecule.
Pancreastatin
has a prohormonal precursor, chromogranin A, which is a glycoprotein present in neuroendocrine cells, including the endocrine pancreas. We have been interested in pancreastatin action in the liver. We found that pancreastatin has a glycogenolytic effect in the hepatocyte both in vivo and in vitro. We then studied and characterized the specific pancreastatin receptor in the rat liver plasma membrane, as well as the specific signal transduction. This receptor appears to be coupled to two different G proteins. A pertussis toxin-insensitive G proteins leads to the activation of
phospholipase C
, and therefore mediates the glycogenolytic effect in the liver by increasing cytoplasmic free calcium and stimulating protein kinase C. The role of cyclic GMP in the action of pancreastatin is not known yet, although it seems to regulate negatively the activation of
phospholipase C
. The precise mechanism by which pancreastatin stimulates guanylate cyclase activity remains to be studied.
...
PMID:Pancreastatin action in the liver: dual coupling to different G proteins. 877 44
Pancreastatin
(
PST
), a recently discovered regulatory peptide derived from chromogranin A, has been shown to have a glycogenolytic effect in the hepatocyte that is mediated by increasing intracellular calcium. Our previous studies on pancreastatin signaling suggested that
PST
receptor is coupled to some G proteins in the plasma membrane of the hepatocyte. The nature of this interaction was investigated using antisera against G(q/11)alpha by different approaches. Indirect evidence of a pertussis toxin (PT)-insensitive G protein of the family of G(q/11)alpha was obtained by measuring high-affinity guanosine triphosphatase (GTPase) activity in soluble rat liver membranes.
PST
increased GTPase activity in a dose-dependent manner. This effect was only slightly inhibited by PT pretreatment of the membranes, whereas anti-G(q/11)alpha antisera blocked most of the
PST
-stimulated GTPase activity. The selective association of the
PST
receptor with this G protein was further studied by the coelution in wheat germ agglutinin semipurification of the receptor and by immunoprecipitation of the G protein-
PST
receptor complexes using G-protein-specific antisera. A G protein of the family of G(q/11)alpha was found to be associated with the semipurified
PST
receptor. Moreover, anti-G(q/11)alpha antisera immunoprecipitated most
PST
-binding activity (95%), bringing down most of the specific G protein, whereas anti-G(il,2)alpha and -G(o,i3)alpha failed to immunoprecipitate the
PST
-binding activity. Finally, the coupling of the
PST
receptor with the effector
phospholipase C
was disrupted by blocking with G(q/11)alpha antisera, suggesting that a G protein of the family of G(q/11)alpha is a signal mediator from
PST
receptors to
phospholipase C
activation in rat liver membranes.
...
PMID:Pancreastatin receptor is coupled to a guanosine triphosphate-binding protein of the G(q/11)alpha family in rat liver membranes. 946 64
Pancreastatin
(
PST
) receptors have been recently shown to mediate activation of
phospholipase C
(
PLC
) in rat liver membranes. There is evidence that the G protein that links pancreastatin receptor with
PLC
-beta is pertussis toxin-insensitive and belongs to the G(alpha)q family. Here, we have employed blocking antisera to sort out the specific
PLC
-beta isoform as well as the specific G(alpha) subunit activated by
PST
receptor in rat liver membranes. The presence of different
PLC
-beta isoforms was checked by immunoblot analysis. Only
PLC
-beta4 was not detected, whereas
PLC
-beta1, beta2 and beta3 were abundant in rat liver membranes. However, only anti-
PLC
-beta3 serum was able to block the
PST
receptor response. We also checked the expression of G(alpha)q and Galpha11 in rat liver membranes by immunoblot. Even though both isoforms were present. only anti-Galpha11 serum was able to block the
PST
receptor response. In order to check the specificity of the blocking antisera, we employed them to block the effect of ADP and thrombin stimulating
PLC
activity in platelet membranes, a system lacking Galpha11. Anti-G(alpha)q but not anti-Galpha11 sera were able to block the agonist stimulated
PLC
activity. These data suggest that
PST
receptor response is mediated by the activation of the beta3 isoform of
PLC
via Galpha11 protein stimulation in rat liver membranes.
...
PMID:Pancreastatin activates beta3 isoform of phospholipase C via G(alpha)11 protein stimulation in rat liver membranes. 980 54
Pancreastatin
(
PST
), a chromogranin A derived peptide with an array of effects in different tissues, has a role as a counterregulatory hormone of insulin action in hepatocytes and adipocytes, regulating glucose, lipid and protein metabolism. We have previously characterized
PST
receptors and signaling in rat hepatocytes, in which
PST
functions as a calcium-mobilizing hormone. In the present work we have studied
PST
receptors as well as the signal transduction pathways generated upon
PST
binding in adipocyte membranes. First, we have characterized
PST
receptors using radiolabeled
PST
as a ligand. Analysis of binding data indicated the existence of one class of binding sites, with a B(max) of 5 fmol/mg of protein and a K(d) of 1 nM. In addition, we have studied the G protein system that couples the
PST
receptor by gamma-(35)S-GTP binding studies. We have found that two G protein systems are involved, pertussis toxin-sensitive and -insensitive respectively. Specific anti-G protein alpha subtype sera were used to block the effect of pancreastatin receptor activation. Galpha(q/11) and to a lesser extent Galpha(i1,2) are activated by
PST
in rat adipocyte membranes. On the other hand, adenylate cyclase activity was not affected by
PST
. Finally, we have studied the specific
phospholipase C
isoform that is activated in response to
PST
. We have found that
PST
receptor is coupled to PLC-beta(3) via Galpha(q/11) activation in adipocyte membranes.
...
PMID:Characterization of pancreastatin receptors and signaling in adipocyte membranes. 1044 97
In the liver, pancreastatin exerts a glycogenolytic effect through interaction with specific receptors, followed by activation of
phospholipase C
and guanylate cyclase.
Pancreastatin
receptor seems to be coupled to two different G protein systems: a pertussis toxin-insensitive G protein that mediates activation of
phospholipase C
, and a pertussis toxin sensitive G protein that mediates the cyclic GMP production. The aim of this study was to identify the specific G protein subtypes coupling pancreastatin receptors in rat liver membranes. GTP binding was determined by using gamma-35S-GTP; specific anti-G protein alpha subtype sera were used to block the effect of pancreastatin receptor activation. Activation of G proteins was demonstrated by the incorporation of the photoreactive GTP analogue 8-azido-alpha-32P-GTP into liver membranes and into specific immunoprecipitates of different Galpha subunits from soluble rat liver membranes.
Pancreastatin
stimulation of rat liver membranes increases the binding of gamma-35S-GTP in a time- and dose-dependent manner. Activation of the soluble receptors still led to the pancreastatin dose-dependent stimulation of gamma-35S-GTP binding. Besides, WGA semipurified receptors also stimulates GTP binding. The binding was inhibited by treatment with anti-Galphaq/11 (85%) and anti-Galphai1,2 (15%) sera, whereas anti-Galphao,i3 serum failed to affect the binding. Finally, pancreastatin stimulates GTP photolabeling of particulate membranes. Moreover, it specifically increased the incorporation of 8-azido-alpha-32P-GTP into Galphaq/11 and Galpha, but not into Galphao,i3 from soluble rat liver membranes. In conclusion, pancreastatin stimulation of rat liver membranes led to the activation of Galphaq/11 and Galphai1,2 proteins. These results suggest that Galphaq/11 and Galphai1,2 may play a functional role in the signaling of pancreastatin receptor by mediating the production of IP3 and cGMP respectively.
...
PMID:G protein G alpha q/11 and G alpha i1,2 are activated by pancreastatin receptors in rat liver: studies with GTP-gamma 35S and azido-GTP-alpha-32P. 1073 41
Pancreastatin
, a chromogranin A-derived peptide widely distributed throughout the neuroendocrine system, has a general inhibitory effect on endocrine secretion and a counterregulatory effect on insulin action. We have recently described the cross-talk of pancreastatin with insulin signaling in rat hepatoma cells (HTC), where it inhibits insulin action and signaling through the serine phosphorylation of the insulin receptor, thereby impairing tyrosine kinase activity. Here, we have characterized pancreastatin receptors and signaling in HTC cells. The pancreastatin effector systems were studied by determining
phospholipase C
activity in HTC membranes and mitogen-activated protein kinase (MAPK) phosphorylation activity in HTC cells. Binding studies with radiolabeled pancreastatin showed a population of high affinity binding sites, with a B(max) of 8 fmol/mg protein and a K(d) of 0.6 nM. Moreover, we assessed the coupling of the receptor with a G protein system by inhibiting the binding with guanine nucleotide and by measuring the GTP binding to HTC membranes. We found that pancreastatin receptor was coupled with a G alpha(q/11) protein which activates
phospholipase C
-beta(1) and
phospholipase C
-beta(3), in addition to MAPK via both beta gamma and alpha(q/11).
...
PMID:Characterization of pancreastatin receptor and signaling in rat HTC hepatoma cells. 1084 19
Pancreastatin
(
PST
), a chromogranin A-derived peptide, has counterregulatory effects on insulin in the hepatocyte and the adipocyte, suggesting a possible role in insulin resistance. The mechanism of
PST
action on glucose and lipid metabolism is typical of a calcium-mobilizing hormone and involves a receptor Gq/11 protein-
phospholipase C
(
PLC
)-beta pathway. In the rat adipocyte,
PST
inhibits insulin-mediated glucose transport, glucose utilization, and lipid synthesis, and it has a lipolytic effect but stimulates basal and insulin-stimulated protein synthesis. We have also recently studied the
PST
receptor-effector system in adipocyte membranes. To further investigate the mechanisms of
PST
effect on insulin action, we studied the cross-talk of
PST
with insulin signaling in the rat adipocyte. We found that
PST
inhibits insulin-stimulated GLUT4 translocation to the membrane, which may explain the reported inhibition of glucose transport. Tyrosine phosphorylation of the activated insulin receptor, insulin receptor substrate (IRS)-1, and p60-70 was also blunted, preventing their association with p85 phosphatidylinositol 3-kinase (PI3K) and their activity. The mechanism of this inhibition involves the activation of the "classical" protein kinase C isoforms and the serine phosphorylation of insulin receptor and IRS-1. On the other hand,
PST
activates the mitogen-activated protein kinase (MAPK) signaling module and enhances the effect of insulin. This pathway may account for the described effect of
PST
on protein synthesis. In conclusion,
PST
seems to inhibit the insulin-stimulated PI3K pathway in the adipocyte, whereas it activates the MAPK pathway. These data provide some clues to the
PST
cross-talk with insulin signaling that may explain the
PST
effects on glucose metabolism and protein synthesis.
...
PMID:Pancreastatin modulates insulin signaling in rat adipocytes: mechanisms of cross-talk. 1092 27
Pancreastatin
(
PST
) is one of the chromogranin A (CGA)-derived peptides with known biological activity. It has a general inhibitory effect on secretion in many exocrine and endocrine systems including the heart atrium. Besides, a role of
PST
as a counter-regulatory peptide of insulin action has been proposed in the light of its effects on glucose and lipid metabolism in the liver and adipose tissue, where receptors and signaling have been described. Galpha(q/11) pathway seems to mediate
PST
action. Since
PST
has been shown to function as a typical calcium-dependent hormone, and increased plasma levels have been found in essential hypertension correlating with catecholamines, we sought to study its possible interaction and signaling in heart membranes. Here, we are characterizing specific
PST
binding sites and signaling in rat heart membranes. We have found that
PST
receptor has a K(d) of 0.5 nM and a B(max) of 34 fmol/mg of protein. The
PST
binding is inhibited by guanine nucleotides, suggesting the functional coupling of the receptor with GTP binding proteins (G proteins). Moreover,
PST
dose-dependently increases GTP binding to rat heart membranes. Finally, we have studied
PST
signaling-effector system by measuring
phospholipase C
(
PLC
) activity using blocking antibodies against different G proteins and
PLC
isoforms. We have found that
PST
stimulates PLCbeta(2)>PLCbeta(1)>PLCbeta(3) by activating Galpha(16) in rat heart membranes. These data suggest that
PST
may modulate the cardiac function.
...
PMID:Pancreastatin, a chromogranin A-derived peptide, activates Galpha(16) and phospholipase C-beta(2) by interacting with specific receptors in rat heart membranes. 1125 46
Pancreastatin
(
PST
), a chromogranin A-derived peptide, has an anti-insulin metabolic effect and inhibits growth and proliferation by producing nitric oxide (NO) in HTC rat hepatoma cells. When NO production is blocked, a proliferative effect prevails due to the activation a Galphaq/11-
phospholipase C
-beta (PLC-beta) pathway, which leads to an increase in [Ca2+]i, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) activation. The aim of the present study was to investigate the NO synthase (NOS) isoform that mediates these effects of
PST
on HTC hepatoma cells and the possible roles of cyclic GMP (cGMP) and cGMP-dependent protein kinase. DNA and protein synthesis in response to
PST
were measured as [3H]-thymidine and [3H]-leucine incorporation in the presence of various pharmacological inhibitors: N-monomethyl-L-arginine (NMLA, nonspecific NOS inhibitor), L-NIO (endothelial nitric oxide synthase (eNOS) inhibitor), espermidine (neuronal nitric oxide synthase (nNOS) inhibitor), LY83583 (guanylyl cyclase inhibitor), and KT5823 (protein kinase G inhibitor, (PKG)). L-NIO, similarly to NMLA, reverted the inhibitory effect of
PST
on hepatoma cell into a stimulatory effect on growth and proliferation. Nevertheless, espermidine also prevented the inhibitory effect of
PST
, but there was no stimulation of growth and proliferation. When guanylyl cyclase activity was blocked, there was again a reversion of the inhibitory effect into a stimulatory action, suggesting that the effect of NO was mediated by the production of cGMP. PKG inhibition prevented the inhibitory effect of
PST
, but there was no stimulatory effect. Therefore, the inhibitory effect of
PST
on growth and proliferation of hepatoma cells may be mainly mediated by eNOS activation. In turn, the effect of NO may be mediated by cGMP, whereas other pathways in addition to PKG activation seem to mediate the inhibition of DNA and protein synthesis by
PST
in HTC hepatoma cells.
...
PMID:eNOS, nNOS, cGMP and protein kinase G mediate the inhibitory effect of pancreastatin, a chromogranin A-derived peptide, on growth and proliferation of hepatoma cells. 1558 12
1
2
Next >>